AZD0486
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Conditions
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Trial Timeline
Dec 29, 2023 → Jun 29, 2027
NCT ID
NCT06137118About AZD0486
AZD0486 is a phase 1/2 stage product being developed by AstraZeneca for B-cell Acute Lymphoblastic Leukemia (B-ALL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06137118. Target conditions include B-cell Acute Lymphoblastic Leukemia (B-ALL).
What happened to similar drugs?
3 of 20 similar drugs in B-cell Acute Lymphoblastic Leukemia (B-ALL) were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06137118 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in B-cell Acute Lymphoblastic Leukemia (B-ALL)